Last updated on July 2019

EXpanded CELL ENdocardiac Transplantation (EXCELLENT)


Brief description of study

The main purpose of this phase I/IIB is to evaluate the safety, the tolerance and the first efficacy trends of intracardiac injection of ProtheraCytes (autologous PB-CD34+ Stem Cells after automated ex-vivo expansion with the StemXpand machine) in patients with a De Novo acute myocardial infarction and decreased ejection fraction. ProtheraCytes will be reinjected using a dedicated catheter pushed through the femoral artery up to the left ventricle, thus avoiding open chest surgery.

Clinical Study Identifier: NCT02669810

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.